Anne MacGregor


Anne MacGregor

National Partner

Brussels | 480 Avenue Louise, Box 13A, Brussels 1050
+32 2 535 5425 | +32 2 535 5400

| vCard | PDF

Anne MacGregor advises clients on EU competition law and antitrust, regulatory and trade matters in a variety of industries. She has over two decades of experience in the Brussels EU arena, representing leading multinational companies and advising hedge funds in complex cross-border transactions relating to merger control filings and antitrust clearance as well as broader EU regulatory issues.

Ms. MacGregor is recognized as a leading lawyer in Brussels for competition/European law in the 2018 edition of Chambers Global, where clients attest to her “superb attention to detail and fine awareness of the economic and political implications of any deal.” She is also recognized in Chambers Europe 2017. Additionally, she was named among the top 100 women in antitrust in 2016 by Global Competition Review (GCR).

Ms. MacGregor is a regular contributor to antitrust and competition publications and a frequent speaker at industry events. She also tutors students in European competition law in the Master of Laws in International and European Law degree program at the Vrije Universiteit Brussel (VUB) and in 2017 was a Visiting Research Fellow at the O.P. Jindal Global University in India where she taught an elective course on International Merger Control.

Prior to joining Dechert, Ms. MacGregor was Special Counsel in the antitrust practice at Cadwalader, Wickersham & Taft. Her previous experience also includes serving as counsel at Baker & McKenzie and Linklaters, working as an associate at Shearman & Sterling and Freshfields Bruckhaus Deringer, and serving as legal counsel and head of the merger analysis team at MLex


Significant Representations

  • Monsanto in its attempt to acquire Syngenta and then merger with Bayer.
  • Salix Pharmaceuticals on its proposed combination with Cosmo Pharmaceuticals, its potential acquisition by Allergan, and its acquisition by Valeant Pharmaceuticals.
  • Deutsche Post DHL on a number of acquisitions and as an interested party during competitors' attempts to acquire TNT Express.
  • Mercuria in its acquisition of a leading global financial services firm’s physical commodities trading business.
  • Élan on the hostile bid for it by Royalty Pharma and its subsequent sale to Perrigo.
  • Aer Lingus in its ongoing battles with Ryanair.
  • Deutsche Boerse on its attempted merger with NYSE Euronext.
  • Abbott Laboratories on its acquisition of Solvay Pharmaceuticals.
  • Ashland on its foundry consumables joint venture and the sale of its distribution business.
  • iSoft on its acquisition by Computer Sciences Corporation.
  • CVC private equity on the successive purchases of three ink producers and proposed drink carton packaging acquisitions.
  • Vattenfall in the establishment of an electric vehicles joint venture.
  • Johnson & Johnson on its acquisition of Pfizer's consumer healthcare business.

Includes matters handled at Dechert or prior to joining the firm.

  • Australian National University, B.A., LL.B. (Hons), 1990
  • University of Hamburg, LL.M., 1993
  • Registered Foreign Lawyer with the French-speaking Brussels bar
  • Solicitor, England and Wales
  • New York
  • Solicitor, Ireland
  • New South Wales
  • Australian Capital Territory

Visiting Research Fellow, Jindal Initiative on Research in IP and Competition, at O.P. Jindal Global University, India (October 23, 2017 - November 3, 2017)

Studienvereinigung Kartellrecht

Law Society of England & Wales

Law Society of Ireland